| 臺大學術典藏 |
2021-01-15T03:47:10Z |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
|
Ch'ang H.-J.; Huang C.-L.; HSIU-PO WANG; Shiah H.-S.; Chang M.-C.; Jan C.-M.; Chen J.-S.; Tien Y.-W.; Hwang T.-L.; Lin J.-T.; Cheng A.-L.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-15T03:47:00Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; HSIU-PO WANG; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; Cheng A.-L.; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-04T12:13:01Z |
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma
|
Whang-Peng J.; Chen L.-T.; HWEI-FANG TIEN; Chao T.-Y.; Hsu C.-H.; Uen W.-C.; Kao W.-Y.; Tsao C.-J.; Chang M.-C.; Chen P.-J.; Su I.-J.; Cheng A.-L.; Hsiung C.A. |
| 臺大學術典藏 |
2020-12-02T02:35:41Z |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein
|
Yang C.-H.;Huang C.-J.;Yang C.-S.;Chu Y.-C.;Cheng A.-L.;Whang-Peng J.;Pan-Chyr Yang; Yang C.-H.; Huang C.-J.; Yang C.-S.; Chu Y.-C.; Cheng A.-L.; Whang-Peng J.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:35:41Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
PAN-CHYR YANG; Yang C.-H.;Chen M.-C.;Cheng A.-L.;Hsu C.-H.;Yeh K.-H.;Yu Y.-C.;Whang-Peng J.;Pan-Chyr Yang; Yang C.-H.; Chen M.-C.; Cheng A.-L.; Hsu C.-H.; Yeh K.-H.; Yu Y.-C.; Whang-Peng J. |
| 臺大學術典藏 |
2020-11-19T03:19:36Z |
Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection
|
Chen L.-T.;Chen M.-F.;Li L.-A.;Po-Huang Lee;Jeng L.-B.;Lin D.-Y.;Wu C.-C.;Mok K.-T.;Chen C.-L.;Lee W.-C.;Chau G.-Y.;Chen Y.-S.;Lui W.-Y.;Hsiao C.-F.;Whang-Peng J.;Chen P.-J.; Chen L.-T.; Chen M.-F.; Li L.-A.; PO-HUANG LEE; Jeng L.-B.; Lin D.-Y.; Wu C.-C.; Mok K.-T.; Chen C.-L.; Lee W.-C.; Chau G.-Y.; Chen Y.-S.; Lui W.-Y.; Hsiao C.-F.; Whang-Peng J.; Chen P.-J. |
| 臺大學術典藏 |
2020-09-30T03:23:35Z |
Reappraisal of the early diagnostic value of serial analyses of Western Blot patterns for HIV infection in Neonates
|
Chen M.-Y.;Chien-Ching Hung;Lin Y.G.;Lin R.-Y.;Twu S.-J.;Ko Y.-C.;Ho H.-N.;Lin C.-P.;Huang S.-F.;Kerrigan M.E.;Whang-Peng J.;Chuang C.-Y.;Chang K.S.S.;Sung J.-L.;Chang H.-J.;Shih Y.-T.;Chang P.-Y.; Chen M.-Y.; CHIEN-CHING HUNG; Lin Y.G.; Lin R.-Y.; Twu S.-J.; Ko Y.-C.; Ho H.-N.; Lin C.-P.; Huang S.-F.; Kerrigan M.E.; Whang-Peng J.; Chuang C.-Y.; Chang K.S.S.; Sung J.-L.; Chang H.-J.; Shih Y.-T.; Chang P.-Y. |
| 國家衛生研究院 |
2020-09-13 |
Astragalus Polysaccharide (PG2) suppresses macrophage migration inhibitory factor and aggressiveness of lung adenocarcinoma cells
|
Liao, CH;Yong, CY;Lai, GM;Chow, JM;Cheng, CF;Fang, CL;Lin, PC;Chang, CL;Zheng, YM;Chuang, SE;Whang-Peng, J;Yao, CJ |
| 國家衛生研究院 |
2020-07-29 |
Omega-3 fatty acid-enriched fish oil and selenium combination modulates endoplasmic reticulum stress response elements and reverses acquired gefitinib resistance in HCC827 lung adenocarcinoma cells
|
Liao, CH;Tzeng, YT;Lai, GM;Chang, CL;Hu, MH;Tsai, WL;Liu, YR;Hsia, S;Chuang, SE;Chiou, TJ;Wang, LM;Whang-Peng, J;Yao, CJ |
| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein
|
Chih-Hsin Yang;Huang C.-J;Yang C.-S;Chu Y.-C;Cheng A.-L;Whang-Peng J;Yang P.-C.; CHIH-HSIN YANG; Huang C.-J; Yang C.-S; Chu Y.-C; Cheng A.-L; Whang-Peng J; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Chih-Hsin Yang;Chen M.-C;Cheng A.-L;Hsu C.-H;Yeh K.-H;Yu Y.-C;Whang-Peng J;Yang P.-C.; CHIH-HSIN YANG; Chen M.-C; Cheng A.-L; Hsu C.-H; Yeh K.-H; Yu Y.-C; Whang-Peng J; Yang P.-C. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J;Wang C.-C;Cheng A.-L;Hsu C;Yen-Shen Lu;Chang M.-C;Lin J.-T;Wang H.-P;Shiah H.-S;Liu T.-W;Chang J.-Y;Whang-Peng J;Chen L.-T.; Ch'ang H.-J; Wang C.-C; Cheng A.-L; Hsu C; YEN-SHEN LU; Chang M.-C; Lin J.-T; Wang H.-P; Shiah H.-S; Liu T.-W; Chang J.-Y; Whang-Peng J; Chen L.-T. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients
|
Su W.-P;Wen C.-C;Hsiung C.A;Su I.-J;Cheng A.-L;Chang M.-C;Tsao C.-J;Kao W.-Y;Uen W.-C;Hsu C.-H;Yen-Shen Lu;Tien H.-F;Chao T.-Y;Chen L.-T;Whang-Peng J;Chen P.-J.; Su W.-P; Wen C.-C; Hsiung C.A; Su I.-J; Cheng A.-L; Chang M.-C; Tsao C.-J; Kao W.-Y; Uen W.-C; Hsu C.-H; YEN-SHEN LU; Tien H.-F; Chao T.-Y; Chen L.-T; Whang-Peng J; Chen P.-J. |
| 臺大學術典藏 |
2020-04-28T07:25:37Z |
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma
|
Cheng A.-L.;Hsiung C.A.;Su I.-J.;Chen P.-J.;Chang M.-C.;Tsao C.-J.;Kao W.-Y.;Uen W.-C.;Chih-Hung Hsu;Tien H.-F.;Chao T.-Y.;Chen L.-T.;Whang-Peng J.; Cheng A.-L.; Hsiung C.A.; Su I.-J.; Chen P.-J.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; CHIH-HUNG HSU; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J. |
| 臺大學術典藏 |
2020-04-28T07:25:36Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Yang C.-H.; Chen M.-C.; Cheng A.-L.; CHIH-HUNG HSU; Yeh K.-H.; Yu Y.-C.; Whang-Peng J.; Yang P.-C.; Yang C.-H.;Chen M.-C.;Cheng A.-L.;Chih-Hung Hsu;Yeh K.-H.;Yu Y.-C.;Whang-Peng J.;Yang P.-C. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.;Cheng A.-L.;Hsu C.;Chih-Hung Hsu;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Hsu C.; CHIH-HUNG HSU; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; CHIH-HUNG HSU; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; Cheng A.-L.; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T.; Ch'Ang H.-J. ;Lin Y.-L. ;Wang H.-P. ;Chiu Y.-F. ;Chang M.-C. ;Chih-Hung Hsu ;Tien Y.-W. ;Chen J.-S. ;Hsieh R.-K. ;Lin P.-W. ;Shan Y.-S. ;Cheng A.-L. ;Chang J.-Y. ;Whang-Peng J. ;Hwang T.-L. ;Chen L.-T. |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Chen L.-T.; Shiah H.-S.;Cheng A.-L.;Chiun Hsu;Hsu C.-H.;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Chiun Hsu; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J. |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J.;Wang C.-C.;Cheng A.-L.;Chiun Hsu;Lu Y.-S.;Chang M.-C.;Lin J.-T.;Wang H.-P.;Shiah H.-S.;Liu T.-W.;Chang J.-Y.;Whang-Peng J.;Chen L.-T.; Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Chiun Hsu; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-10T12:51:18Z |
Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma
|
Whang-Peng J.;Cheng A.-L.;Chiun Hsu;Chen C.-M.; Whang-Peng J.; Cheng A.-L.; Chiun Hsu; Chen C.-M. |
| 臺大學術典藏 |
2020-02-20T06:53:15Z |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
|
Ch'ang H.-J.; Shiah H.-S.; Chang M.-C.; Jan C.-M.; Chen J.-S.; YU-WEN TIEN; Hwang T.-L.; Lin J.-T.; Cheng A.-L.; Whang-Peng J.; Chen L.-T.; Wang H.-P.; Huang C.-L. |
| 臺大學術典藏 |
2020-02-20T06:53:13Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T.; Shan Y.-S.; Cheng A.-L.; Lin P.-W.; Chen J.-S.; Hsieh R.-K.; YU-WEN TIEN; Ch'Ang H.-J.;Lin Y.-L.;Wang H.-P.;Chiu Y.-F.;Chang M.-C.;Hsu C.-H.;Yu-Wen Tien;Chen J.-S.;Hsieh R.-K.;Lin P.-W.;Shan Y.-S.;Cheng A.-L.;Chang J.-Y.;Whang-Peng J.;Hwang T.-L.;Chen L.-T.; Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2020-02-14T02:49:59Z |
The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine
|
Wei H.-J.;Wu A.T.;Hsu C.-H.;Lin Y.-P.;Wen-Fang Cheng;Su C.-H.;Chiu W.-T.;Whang-Peng J.;Douglas F.L.;Deng W.-P.; Wei H.-J.; Wu A.T.; Hsu C.-H.; Lin Y.-P.; WEN-FANG CHENG; Su C.-H.; Chiu W.-T.; Whang-Peng J.; Douglas F.L.; Deng W.-P. |
| 臺大學術典藏 |
2020-02-06T08:11:26Z |
A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit
|
Liaw Y.-W.; Lin C.-Y.; Lai Y.-S.; Yang T.-C.; Wang C.-J.; Whang-Peng J.; Liu L.F.; Lin C.-P.; Nieh S.; SHAO-CHUN LU; Hwang J. |
| 臺大學術典藏 |
2020-02-06T05:22:12Z |
The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine
|
Deng W.-P.;Douglas F.L.;Whang-Peng J.;Chiu W.-T.;Su C.-H.;WEN-FANG CHENG;Lin Y.-P.;Hsu C.-H.;Wu A.T.;Wei H.-J.; Wei H.-J.; Wu A.T.; Hsu C.-H.; Lin Y.-P.; WEN-FANG CHENG; Su C.-H.; Chiu W.-T.; Whang-Peng J.; Douglas F.L.; Deng W.-P.; Wei H.-J.; Wu A.T.; Hsu C.-H.; Lin Y.-P.; WEN-FANG CHENG; Su C.-H.; Chiu W.-T.; Whang-Peng J.; Douglas F.L.; Deng W.-P. |
